KR20220167014A - A composition for preventing or treating of sarcopenia containing compounds isolated from allium tuberosum - Google Patents
A composition for preventing or treating of sarcopenia containing compounds isolated from allium tuberosum Download PDFInfo
- Publication number
- KR20220167014A KR20220167014A KR1020210076030A KR20210076030A KR20220167014A KR 20220167014 A KR20220167014 A KR 20220167014A KR 1020210076030 A KR1020210076030 A KR 1020210076030A KR 20210076030 A KR20210076030 A KR 20210076030A KR 20220167014 A KR20220167014 A KR 20220167014A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- present
- compound
- differentiation
- preventing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 208000001076 sarcopenia Diseases 0.000 title claims abstract description 28
- 244000003377 Allium tuberosum Species 0.000 title abstract description 3
- 235000005338 Allium tuberosum Nutrition 0.000 title abstract description 3
- 230000004069 differentiation Effects 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 210000000663 muscle cell Anatomy 0.000 claims abstract description 15
- 230000012010 growth Effects 0.000 claims abstract description 14
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims abstract description 13
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims abstract description 13
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims abstract description 12
- 108091007960 PI3Ks Proteins 0.000 claims abstract description 12
- 230000001939 inductive effect Effects 0.000 claims abstract description 5
- 240000006108 Allium ampeloprasum Species 0.000 claims description 15
- 235000005254 Allium ampeloprasum Nutrition 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000019491 signal transduction Effects 0.000 claims description 13
- 235000013376 functional food Nutrition 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 11
- 230000004913 activation Effects 0.000 claims description 7
- 210000003205 muscle Anatomy 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 14
- 235000013305 food Nutrition 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000037361 pathway Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- -1 aromatic sulfonic acids Chemical class 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000002027 skeletal muscle Anatomy 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 210000002363 skeletal muscle cell Anatomy 0.000 description 6
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003098 myoblast Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 235000001270 Allium sibiricum Nutrition 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
- 238000010599 BrdU assay Methods 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012223 aqueous fraction Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- JIRHAGAOHOYLNO-UHFFFAOYSA-N (3-cyclopentyloxy-4-methoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C=C1OC1CCCC1 JIRHAGAOHOYLNO-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- MNURPFVONZPVLA-UHFFFAOYSA-N 2-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1Cl MNURPFVONZPVLA-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- VYWYYJYRVSBHJQ-UHFFFAOYSA-N 3,5-dinitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 VYWYYJYRVSBHJQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- YBTWWWIJBCCYNR-UAKXSSHOSA-N 5-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 YBTWWWIJBCCYNR-UAKXSSHOSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000004472 Myostatin Human genes 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N ortho-methoxybenzoic acid Natural products COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 근감소증의 예방, 개선 또는 치료용 조성물에 관한 것으로, 보다 구체적으로는 부추에서 분리된 화합물 또는 이의 염을 포함하는 근감소증의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, improving or treating sarcopenia, and more particularly, to a composition for preventing, improving or treating sarcopenia comprising a compound isolated from leek or a salt thereof.
노화에 따라 골격근 질량과 근력의 손실이 발생하게 되는데, 이를 근감소증 (sarcopenia)이라고 한다. 근감소증은 대략 30 세에 시작되어 평생 진행되는 과정으로 근육 조직량과 금섬유 수 및 크기가 점진적으로 감소하여 근육량과 근력의 손실이 발생한다. 이로 인해 운동성의 소실, 낙상, 골다공증, 골절로 인한 삶의 질 저하 및 신체 활동 감소를 초래한다. 최근 고령 인구의 증가로 유병률이 높아지고 있으며 이로 인한 의료비 부담이 증가함에 따라 이를 낮출 수 있는 연구의 필요성이 강조되고 있다. 따라서 많은 연구자들이 천연물로부터 골격근 질량을 늘리고 유지하는 데 도움이 될 수 있는 성분을 찾는 연구를 활발히 진행하고 있다.Aging causes a loss of skeletal muscle mass and strength, which is called sarcopenia. Sarcopenia is a lifelong process that begins at about the age of 30, and the amount of muscle tissue and the number and size of gold fibers gradually decrease, resulting in loss of muscle mass and strength. As a result, loss of mobility, falls, osteoporosis, and fractures result in decreased quality of life and decreased physical activity. Recently, the prevalence is increasing due to the increase in the elderly population, and as the burden of medical expenses increases due to this, the need for research that can lower it is emphasized. Therefore, many researchers are actively conducting research to find ingredients from natural products that can help increase and maintain skeletal muscle mass.
한편, 부추 (Allium tuberosum)는 백합과 (Liliaceae)에 속하는 여러해살이 풀로서, 주로 동아시아와 동남아시아에서 재배하고 소비되며 중국에서는 복통, 설사, 토혈, 천식의 치료를 위해 사용되어왔다. 부추의 약리활성에 대한 연구로는 항 당뇨 및 간 보호 효과, 혈청 콜레스레롤, 트리글리세리드, 저밀도 지단백 콜레스테롤 및 동맥경화지표 감소에 의한 지질개선효과, 세포사멸을 통한 암세포 증식 억제 효과(KOREAN J.FOOD SCI. TECHNOL. Vol. 34. No.4 pp. 688~693 (2002)) 등이 보고되어 있으나 골격근 세포 분화 효과에 대한 보고는 아직 없어, 이에 대한 연구가 필요한 실정이다.On the other hand, leek (Allium tuberosum) is a perennial herb belonging to the Liliaceae family, and is mainly cultivated and consumed in East and Southeast Asia, and has been used for the treatment of abdominal pain, diarrhea, hematemesis, and asthma in China. Studies on the pharmacological activity of chives include antidiabetic and hepatoprotective effects, lipid improvement effects by reducing serum cholesterol, triglyceride, low-density lipoprotein cholesterol and arteriosclerosis index, and cancer cell proliferation inhibition effects through apoptosis (KOREAN J.FOOD SCI.
본 발명자들은 근감소증을 치료를 위한 천연물을 예의 연구한 결과, 부추로부터 화합물을 분리하였고, 상기 화합물이 PI3K/Akt/mTOR 조절하는 조절인자로 작용하여 근육세포의 성장과 분화를 유의적으로 유도함으로써 근감소증 예방 및 치료용 조성물로 유용하게 사용될 수 있음을 확인하였다.As a result of intensive research on natural products for the treatment of sarcopenia, the present inventors isolated a compound from leek, and the compound acts as a regulator that regulates PI3K/Akt/mTOR and significantly induces the growth and differentiation of muscle cells. It was confirmed that it can be usefully used as a composition for preventing and treating sarcopenia.
이에, 본 발명은 하기 화학식 1로 표시되는 화합물 또는 이들의 약학적으로 허용가능한 염을 포함하는, 근감소증 예방 또는 치료용 약학적 조성물을 제공하는 것을 목적으로 한다.Accordingly, an object of the present invention is to provide a pharmaceutical composition for preventing or treating sarcopenia, comprising a compound represented by Formula 1 below or a pharmaceutically acceptable salt thereof.
[화학식 1][Formula 1]
또한, 본 발명은 상기 화합물 또는 이들의 식품학적으로 허용가능한 염을 유효성분으로 포함하는, 근감소증 예방 또는 개선용 건강기능식품 조성물을 제공하는 것을 또 다른 목적으로 한다.In addition, another object of the present invention is to provide a health functional food composition for preventing or improving sarcopenia, comprising the compound or a pharmaceutically acceptable salt thereof as an active ingredient.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problems, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.
상기와 같은 목적을 달성하기 위하여, 본 발명은 하기 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용가능한 염을 포함하는, 근감소증 예방 또는 치료용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating sarcopenia comprising a compound represented by Formula 1 below or a pharmaceutically acceptable salt thereof.
[화학식 1][Formula 1]
또한, 본 발명은 상기 화합물 또는 이들의 식품학적으로 허용가능한 염을 유효성분으로 포함하는, 근감소증 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving sarcopenia, comprising the compound or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 일구현예로, 상기 화합물은 근손실 억제 활성을 가질 수 있다.In one embodiment of the present invention, the compound may have muscle loss inhibitory activity.
본 발명의 다른 구현예로, 상기 화합물은 근육세포의 성장 및 분화를 유도할 수 있다.In another embodiment of the present invention, the compound can induce the growth and differentiation of muscle cells.
본 발명의 또 다른 구현예로, 상기 화합물은 PI3K/Akt/mTOR 신호 전달 경로의 활성화를 통해 근육세포의 성장 및 분화를 유도시킬 수 있다.In another embodiment of the present invention, the compound can induce the growth and differentiation of muscle cells through the activation of the PI3K/Akt/mTOR signaling pathway.
본 발명의 또 다른 구현예로, 상기 화합물은 부추로부터 추출 및 분리된 것일 수 있다.In another embodiment of the present invention, the compound may be extracted and isolated from leek.
상기 화합물이 PI3K/Akt/mTOR 경로를 조절하는 조절인자로 작용하여 근육세포의 성장과 분화를 유의적으로 유도함으로써 근감소증 예방 및 치료를 위한 의약품, 식품, 의약외품으로 널리 활용할 수 있을 것으로 기대된다.It is expected that the compound can be widely used as a medicine, food, or quasi-drug for the prevention and treatment of sarcopenia by significantly inducing the growth and differentiation of muscle cells by acting as a regulator that regulates the PI3K/Akt/mTOR pathway.
도 1은 부추 추출물로부터 본 발명에 따른 화합물을 분리하는 과정을 모식도로 나타낸 것이다.
도 2는 본 발명의 따른 화합물의 골격근 세포 분화 활성을 확인한 것으로, 도 2a는 본 발명의 화합물의 세포 독성을 확인한 결과를 나타낸 것이고, 도 2b는 myoblast 세포 분화를 확인한 결과를 나타낸 것이다.
도 3은 본 발명에 따른 화합물의 골격근 성장과 관련한 PI3K/Akt/mTOR 신호 전달 경로의 활성화를 확인한 것으로, 도 3a는 Western blot을 이용하여 골격근 분화와 관련된 6개의 단백질의 발현 수준의 변화를 확인한 결과를 나타낸 것이고, 도 3b 내지 3g는 도 3a에 개시된 각 단백질 발현 수준의 정도를 정량화한 결과를 나타낸 것이다.
도 4는 Myostatin 및 IGF-1의 메커니즘에 따른 골격근 분화 조절 경로를 나타낸 모식도이다.Figure 1 is a schematic diagram showing the process of separating the compound according to the present invention from the leek extract.
Figure 2 confirms the skeletal muscle cell differentiation activity of the compound according to the present invention, Figure 2a shows the result of confirming the cytotoxicity of the compound of the present invention, Figure 2b shows the result confirming the myoblast cell differentiation.
Figure 3 confirms the activation of the PI3K/Akt/mTOR signaling pathway related to skeletal muscle growth by the compound according to the present invention, and Figure 3a shows the result of confirming the change in the expression level of six proteins related to skeletal muscle differentiation using Western blot. 3b to 3g show the results of quantifying the degree of expression of each protein described in FIG. 3a.
Figure 4 is a schematic diagram showing the skeletal muscle differentiation control pathway according to the mechanism of Myostatin and IGF-1.
본 발명자들은 부추로부터 화합물을 분리하였고, 상기 화합물이 PI3K/Akt/mTOR 신호 전달 경로를 조절하는 조절인자로 작용하여 근육세포의 성장과 분화를 유의적으로 유도함으로써 근감소증 예방 및 치료용 조성물로 유용하게 사용될 수 있음을 확인하고, 본 발명을 완성하였다.The present inventors isolated a compound from leek, and the compound acts as a regulator that regulates the PI3K/Akt/mTOR signal transduction pathway and significantly induces the growth and differentiation of muscle cells, thereby being useful as a composition for preventing and treating sarcopenia. It was confirmed that it can be used, and the present invention was completed.
이에, 본 발명은 하기 화학식 1로 표시되는 화합물 또는 이의 약학적 또는 식품학적으로 허용가능한 염을 포함하는, 근감소증 예방, 개선 또는 치료용 약학적 조성물 및 건강기능식품 조성물을 제공한다.Accordingly, the present invention provides a pharmaceutical composition and a health functional food composition for preventing, improving, or treating sarcopenia, including a compound represented by Formula 1 below or a pharmaceutically or food-acceptable salt thereof.
[화학식 1][Formula 1]
본 발명에 따른 화합물은 화학식 C9H14N3O6로 구성되고, 5-aminouridine 로 명명되는 화합물을 의미한다.The compound according to the present invention is composed of the chemical formula C 9 H 14 N 3 O 6 and refers to a compound named 5-aminouridine.
본 발명에서 사용되는 용어, "예방"이란 본 발명에 따른 조성물의 투여에 의해 근감소증을 억제시키거나 발병을 지연시키는 모든 행위를 의미한다.As used herein, the term "prevention" refers to all activities to suppress or delay the onset of sarcopenia by administration of the composition according to the present invention.
본 발명에서 사용되는 용어 "개선"이란 본 발명의 따른 조성물의 투여로 근감소증의 정도를 감소시키거나, 근감소증에 의한 합병증 등의 증상을 경감시키는 모든 행위를 의미한다The term "improvement" used in the present invention refers to all activities that reduce the degree of sarcopenia or alleviate symptoms such as complications caused by sarcopenia by administering the composition according to the present invention.
본 발명에서 사용되는 용어, "치료"란 본 발명에 따른 조성물의 투여에 의해 근감소증에 대한 증세가 호전되거나 이롭게 변경되는 모든 행위를 의미한다.As used herein, the term "treatment" refers to all activities in which symptoms of sarcopenia are improved or beneficially changed by administration of the composition according to the present invention.
본 발명에서 상기 화합물은 근손실 억제 활성을 가질 수 있으며, 구체적으로 근육세포의 성장 및 분화를 유도시킴으로써 근손실 억제 활성을 나타낼 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the compound may have muscle loss inhibitory activity, and specifically, may exhibit muscle loss inhibitory activity by inducing growth and differentiation of muscle cells, but is not limited thereto.
본 발명의 화합물은 특정 신호전달경로의 활성화 또는 하향조절을 통해 근육세포의 성장 및 분화를 유도할 수 있으며, 바람직하게는 PI3K/Akt/mTOR 신호 전달 경로의 활성화를 통해 근육세포의 성장 및 분화를 유도할 수 있으나, 이에 제한되는 것은 아니다.The compounds of the present invention can induce the growth and differentiation of muscle cells through the activation or down-regulation of specific signaling pathways, and preferably through the activation of the PI3K/Akt/mTOR signaling pathway, the growth and differentiation of muscle cells. It can be induced, but is not limited thereto.
본 발명의 화합물은 부추로부터 추출 및 분리된 것일 수 있으나, 이에 제한되는 것은 아니다.The compound of the present invention may be extracted and isolated from leek, but is not limited thereto.
본 발명에 따른 [화학식 1]로 표시되는 화합물은 염의 형태로 사용될 수 있다. 상기 염으로는 약학적 또는 식품학적으로 허용되는 다양한 유기산 또는 무기산에 의해 형성된 산부가염을 사용할 수 있다. 산 부가염은 염산, 질산, 인산, 황산, 브롬화수소산, 요오드화수소산, 아질산 또는 아인산과 같은 무기산류와 지방족 모노 및 다이카르복실레이트, 페닐-치환된 알카노에이트, 하이드록시 알카노에이트 및 알칸디오에이트, 방향족 산류, 지방족 및 방향족 설폰산류와 같은 무독성 유기산으로부터 얻을 수 있다. 이러한 무독성 염류로는 설페이트, 피로설페이트, 바이설페이트, 설파이트, 바이설파이트, 니트레이트, 포스페이트, 모노하이드로겐 포스페이트, 디하이드로겐 포스페이트, 메타포스페이트, 피로포스페이트 클로라이드, 브로마이드, 아이오다이드, 플루오라이드, 아세테이트, 프로피오네이트, 데카노에이트, 카프릴레이트, 아크릴레이트, 포메이트, 이소부티레이트, 카프레이트, 헵타노에이트, 프로피온산, 옥살산, 말론산, 숙신산, 수베레이트, 세바케이트, 푸마렝트, 말리에이트, 부틴-1,4-디오에이트, 헥산-1,6-디온산, 벤조산, 클로로벤조산, 메틸벤조산, 디니트로 벤조산, 하이드록시벤조에이트, 메톡시벤조산, 프달산, 테레프달레이트, 벤젠실폰산, 톨루엔실폰산, 클로로벤젠설폰산, 크실렌설폰산, 페닐아세트산, 페닐프로피온산, 페닐부티레이트, 시트레이트, 락테이트, β-하이드록시부티레이트, 글리콜레이트, 말레이트, 타트레이트, 메탄설포네이트, 프로판설포네이트, 나프탈렌-1-설포네이트, 나프탈렌-2-설포네이트, 만델레이트, 트라이플루오로아세트산 등을 사용하여 제조할 수 있다.The compound represented by [Formula 1] according to the present invention may be used in the form of a salt. As the salt, acid addition salts formed by various organic or inorganic acids that are pharmaceutically or food-acceptable may be used. Acid addition salts are formed with inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid and aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, hydroxy alkanoates and alkanedios. It can be obtained from non-toxic organic acids such as oxalates, aromatic acids, aliphatic and aromatic sulfonic acids. These non-toxic salts include sulfate, pyrosulfate, bisulphate, sulphite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride. , acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propionic acid, oxalic acid, malonic acid, succinic acid, suberate, sebacate, fumarent, malic acid Eight, butyne-1,4-dioate, hexane-1,6-dioic acid, benzoic acid, chlorobenzoic acid, methylbenzoic acid, dinitrobenzoic acid, hydroxybenzoate, methoxybenzoic acid, pdalic acid, terepdalate, benzene Silphonic acid, toluenesulfonic acid, chlorobenzenesulfonic acid, xylenesulfonic acid, phenylacetic acid, phenylpropionic acid, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, It can be prepared using propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, trifluoroacetic acid and the like.
이때, 본 발명에 따른 상기 산 부가염은 통상의 방법, 예를들면 [화학식 1]의 화합물을 과량의 산 수용액에 용해시키고, 이 염을 수혼화성 유기용매, 예를들면 메탄올, 에탄올, 아세톤 또는 아세토니트릴을 사용하여 침전시켜서 제조할 수 있다. 또한 이 혼합물에서 용매나 과량의 산을 증발시킨 후 건조시키거나, 또는 석출된 염을 흡입 여과시켜 제조할 수도 있다. At this time, the acid addition salt according to the present invention is prepared by a conventional method, for example, dissolving the compound of Formula 1 in an excess acid aqueous solution, and adding the salt to a water-miscible organic solvent such as methanol, ethanol, acetone or It can be prepared by precipitation using acetonitrile. It can also be prepared by evaporating the solvent or excess acid from this mixture and then drying it, or by suction filtering the precipitated salt.
또한, 본 발명에 따른 [화학식 1]로 표시되는 화합물은 염기를 사용하여 약학적 또는 식품학적으로 허용 가능한 금속염을 만들 수 있다. 알칼리 금속 또는 알칼리 토금속 염은 예를 들면, 화합물을 과량의 알칼리 금속 수산화물 또는 알칼리 토금속 수산화물 용액 중에 용해하고, 비용해 화합물 염을 여과하고, 여액을 증발, 건조시켜 얻는다. 이때, 금속염으로는 리튬, 나트륨, 칼륨 또는 칼슘염을 제조하는 것이 농약학상 적합하다. 또한, 이에 대응하는 은 염은 알칼리 금속 또는 알칼리 토금속 염을 적당한 은염(예를들면, 질산은)과 반응시켜 얻을 수 있다.In addition, the compound represented by [Formula 1] according to the present invention can be made into a pharmaceutically or food-acceptable metal salt using a base. An alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and evaporating and drying the filtrate. At this time, it is suitable for agrochemicals to prepare lithium, sodium, potassium or calcium salts as metal salts. In addition, the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (for example, silver nitrate).
본 발명자들은 구체적인 실시예를 통해 본 발명에 따른 화합물의 근감소증 예방, 개선 및 치료 용도를 규명하였다.The present inventors have identified the use of the compound according to the present invention for preventing, improving, and treating sarcopenia through specific examples.
구체적으로, 본 발명의 일실시예에서는 본 발명에 따른 화합물이 50 μM 농도에서 C2C12 세포에 대한 독성을 나타내지 않으며, myoblast 세포의 분화를 유의적으로 증가시킴으로써, 골격근 성장 조절 효과를 나타낸다는 것을 확인하였다(실시예 2 참조).Specifically, in one embodiment of the present invention, it was confirmed that the compound according to the present invention does not exhibit toxicity to C2C12 cells at a concentration of 50 μM and exhibits a skeletal muscle growth regulating effect by significantly increasing the differentiation of myoblast cells. (See Example 2).
또한, 본 발명의 다른 실시예에서는 본 발명에 따른 화합물이 p-PI3K, p-Akt, p-FoxO1, p-mTOR 및 p-70S6K 단백질의 발현수준을 증가시킴으로써 PI3k/Akt/mTOR 신호 전달 경로를 활성화시켜 근육세포의 성장을 유도시킬 수 있음을 확인하였다(실시예 3 참조).In another embodiment of the present invention, the compound according to the present invention increases the expression levels of p-PI3K, p-Akt, p-FoxO1, p-mTOR and p-70S6K proteins, thereby inhibiting the PI3k/Akt/mTOR signaling pathway. It was confirmed that growth of muscle cells could be induced by activation (see Example 3).
상기 실시예 결과를 종합해보면, 본 발명에 따른 화합물은 골격근의 생성 및 분화를 유도함으로써 근감소증 개선에 효과가 있으며, 근감소증의 예방, 개선 및 치료를 위한 의약품, 식품, 의약외품으로 널리 활용될 수 있음이 기대된다.Summarizing the results of the above examples, the compound according to the present invention is effective in improving sarcopenia by inducing the generation and differentiation of skeletal muscle, and can be widely used as pharmaceuticals, foods, and quasi-drugs for the prevention, improvement, and treatment of sarcopenia. It is expected that there is
본 발명에 따른 조성물이 약학적 조성물의 형태인 경우, 약학적으로 유효한 양으로 [화학식 1]의 화합물을 단독으로 포함하거나 하나 이상의 약학적으로 허용되는 담체를 포함할 수 있다. 이때, 약학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아고무, 인산칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세 결정성 셀룰로스, 폴리비닐 피로리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필 히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 또한, 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.When the composition according to the present invention is in the form of a pharmaceutical composition, it may contain the compound of [Formula 1] alone or one or more pharmaceutically acceptable carriers in a pharmaceutically effective amount. At this time, the pharmaceutically acceptable carrier is one commonly used in the formulation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose , polyvinyl pyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, but are not limited thereto. In addition to the above components, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, and the like may be further included.
본 발명의 약학적 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구투여 (예를 들어, 정맥 내, 피하, 복강 내 또는 국소에 적용)할 수 있으며, 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 시간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.The pharmaceutical composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically applied) depending on the desired method, and the dosage is dependent on the patient's condition, body weight, and disease. Depending on the degree, drug form, administration route and time, it can be appropriately selected by those skilled in the art.
본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에 있어서 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효용량 수준은 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명에 따른 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level depends on the type of disease, severity, activity of the drug, and drug sensitivity, time of administration, route of administration and excretion rate, duration of treatment, factors including concomitantly used drugs, and other factors well known in the medical arts. The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple times. Considering all of the above factors, it is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects, which can be easily determined by those skilled in the art.
구체적으로 본 발명의 약학적 조성물의 유효량은 환자의 연령, 성별, 상태, 체중, 체내에 활성 성분의 흡수도, 불활성율 및 배설속도, 질병종류, 병용되는 약물에 따라 달라질 수 있으며, 일반적으로는 체중 1 kg 당 1 내지 500 mg을 매일 또는 격일 투여하거나, 1일 1 내지 3회로 나누어 투여할 수 있다. 그러나 투여 경로, 성별, 체중, 연령 등에 따라서 증감 될 수 있으므로 상기 투여량이 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, condition, body weight, absorption rate, inactivation rate and excretion rate of the active ingredient in the body, type of disease, and concomitant drugs, generally 1 to 500 mg per 1 kg of body weight may be administered daily or every other day, or divided into 1 to 3 times a day. However, since it may increase or decrease depending on the route of administration, gender, weight, age, etc., the dosage is not limited to the scope of the present invention in any way.
본 발명의 다른 양태로서, 본 발명은 상기 약학적 조성물을 개체에 투여하는 단계를 포함하는 근감소증 치료 방법을 제공한다.As another aspect of the present invention, the present invention provides a method for treating sarcopenia comprising administering the pharmaceutical composition to a subject.
본 발명에서 "개체"는 쥐, 가축, 생쥐, 인간 등 포유류일 수 있으며, 구체적으로 항암치료가 필요한 반려견, 경주마, 인간 등일 수 있고, 바람직하게는 인간일 수 있다.In the present invention, the "individual" may be a mammal such as a rat, livestock, mouse, or human, and may specifically include a companion dog, a racehorse, or a human in need of anticancer treatment, preferably a human.
본 발명의 또 다른 양태로서, 본 발명은 상기 약학적 조성물의 근감소증 치료 용도를 제공한다.As another aspect of the present invention, the present invention provides a use of the pharmaceutical composition for the treatment of sarcopenia.
본 발명에 따른 조성물이 건강기능식품 조성물의 형태로 이용되는 경우, 특정보건용 식품, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 가공된 의학 및 의료효과가 높은 식품으로 제조 될 수 있으며, 상기 식품은 경우에 따라, 기능성식품, 건강식품, 건강보조식품으로 혼용될 수 있으며, 유용한 효과를 얻기 위하여 정제, 캅셀, 분말, 과립, 액상, 환 등의 다양한 형태로 제조될 수 있다.When the composition according to the present invention is used in the form of a health functional food composition, it can be prepared as a food with high medical and medical effects processed to efficiently display bioregulatory functions in addition to specific health food and nutrition supply, and the food Depending on the case, it can be mixed with functional food, health food, and health supplement food, and can be prepared in various forms such as tablets, capsules, powders, granules, liquids, pills, etc. to obtain useful effects.
본 발명의 건강기능식품은 식품 조성물에 통상적으로 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예들 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. 또한, 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 디히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시 톨루엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 첨가할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용될 수 있다.The health functional food of the present invention may include additional ingredients that are commonly used in food compositions to improve smell, taste, and vision. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like may be included. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), and copper (Cu) may be included. In addition, amino acids such as lysine, tryptophan, cysteine, and valine may be included. In addition, preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dihydroacetate, etc.), disinfectants (bleaching powder, high bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxytoluene (BHT) ), etc.), coloring agents (tar color, etc.), coloring agents (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite, etc.), seasonings (MSG sodium glutamate, etc.), sweeteners (dulcin, cyclemate, saccharin, sodium, etc.), Food additives such as flavoring (vanillin, lactones, etc.), leavening agent (alum, D-potassium hydrogentartrate, etc.), strengthening agent, emulsifier, thickener (thickener), coating agent, gum base agent, foam inhibitor, solvent, improver, etc. can be added. The additive may be selected according to the type of food and used in an appropriate amount.
본 발명의 건강기능식품을 식품 첨가물로 사용할 경우, 이를 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.When the health functional food of the present invention is used as a food additive, it may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to conventional methods.
본 발명의 건강기능식품에 있어서, 본 발명에 따른 [화학식 1]의 화합물 함량은 특별히 제한되지 않으며, 투여 대상의 상태, 구체적인 병증의 종류, 진행 정도 등에 따라 다양하게 변경될 수 있다. 필요한 경우, 식품의 전체 함량으로도 포함될 수 있다.In the health functional food of the present invention, the content of the compound of [Formula 1] according to the present invention is not particularly limited, and may be variously changed depending on the condition of the subject to be administered, the type of specific disease, and the degree of progression. If necessary, it may also be included in the total content of food.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, these examples are intended to illustrate the present invention by way of example, and the scope of the present invention is not limited to these examples.
[실시예][Example]
실시예 1. 부추 유래 화합물의 분리 및 실험방법Example 1. Separation and testing of leek-derived compounds
1-1. 부추 추출물 제조1-1. leek extract preparation
전라도 나주 지방 원산지의 부추를 구매하여 사용하였으며, 부추의 지상부 4.0kg을 40℃에서 하루 동안 건조하여 건조 중량 450g을 수득하였다. 수득된 건조중량을 메탄올로 30℃에서 3시간씩 3회 초음파 추출하여 감압 농축기로 농축하여 용매를 제거한 후 83.7g의 농축물을 수득하였다.Chives native to Naju, Jeolla-do were purchased and used, and 4.0 kg of the above-ground part of the chives was dried at 40 ° C. for one day to obtain a dry weight of 450 g. The obtained dry weight was ultrasonically extracted with methanol at 30° C. for 3 hours each time, concentrated in a vacuum concentrator to remove the solvent, and 83.7 g of the concentrate was obtained.
1-2. 부추 추출물로부터 화합물 분리1-2. Isolation of compounds from leek extract
실시예 1-1에서 수득한 83.7 g의 부추 메탄올 추출물을 물에 현탁한 후 분획 깔대기를 이용하여 Hexane, CH2Cl2, 및 EtOAc 로 분획한 뒤 남은 물 분획물을 감압 농축하여 총 71.5g 의 물 분획 농축물을 수득하였다. 물분획물은 25%, 50%, 그리고 75% 메탄올로 Diaion HP-20 컬럼 크로마토그래피를 실시하여 3개의 소 분획으로 구분되었으며, 이중 W2B분획을 다시 CHCl3-MeOH-Water(2:1:0.2)로 실리카겔 컬럼 크로마토그래피를 실시한 후 7% acetonitrile로 prep-HPLC를 실시하여 하기 [화학식 1]의 화합물(3.3 mg)을 분리하였다. (white amorphous powder; C9H13N3O6, HR-ESI-MS m/z 260.0873 [M + H]+ (calcd for C9H14N3O6, 260.0883); for 1H (CD3OD, 400 MHz) and 13C NMR (CD3OD, 100 MHz) spectroscopic data).83.7 g of leek methanol extract obtained in Example 1-1 was suspended in water, and then fractionated with Hexane, CH 2 Cl 2 , and EtOAc using a separatory funnel, and the remaining water fraction was concentrated under reduced pressure to obtain a total of 71.5 g of water. A fraction concentrate was obtained. The water fraction was divided into three small fractions by Diaion HP-20 column chromatography with 25%, 50%, and 75% methanol, and the W2B fraction was again analyzed with CHCl 3 -MeOH-Water (2:1:0.2). After silica gel column chromatography was performed, prep-HPLC was performed with 7% acetonitrile to isolate the compound (3.3 mg) of [Formula 1] below. (white amorphous powder; C 9 H 13 N 3 O 6 , HR-ESI-MS m/z 260.0873 [M + H] + (calcd for C 9 H 14 N 3 O 6 , 260.0883); for 1 H (CD3OD, 400 MHz) and 13 C NMR (CD3OD, 100 MHz) spectroscopic data).
[화학식 1][Formula 1]
1-3. 골격근 세포 배양1-3. Skeletal muscle cell culture
마우스의 myoblasts 세포 라인인 C2C12 세포를 American Type Culture Collection (ATCC, Manassas, VA, USA)에서 구입하였다. 또한, DMEM, 소 태아 혈청(FBS), 말 혈청(HS), 페니실린-스트렙토마이신, 트립신-EDTA 및 DPBS는 Gibco-BRL(Burlington, Ont, Canada)에서 구입하였다. C2C12 세포는 10%의 heat-inactivated FBS, 스트렙토마이신(100 mg/mL) 및 페니실린(100 unit/mL)을 포함하는 DMEM에서 37℃, 5% CO2 가습 배양 조건하에서 유지되었다. 분화를 유도하기 위해 격일로 배지를 변경하면서 80 % confluent 배양액을 6일 동안 2% HS를 포함하는 DMEM으로 전환하였다.C2C12 cells, a mouse myoblasts cell line, were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). In addition, DMEM, fetal bovine serum (FBS), horse serum (HS), penicillin-streptomycin, trypsin-EDTA and DPBS were purchased from Gibco-BRL (Burlington, Ont, Canada). C2C12 cells were maintained in DMEM containing 10% heat-inactivated FBS, streptomycin (100 mg/mL) and penicillin (100 unit/mL) at 37°C and 5% CO 2 under humidified culture conditions. To induce differentiation, 80% confluent cultures were switched to DMEM containing 2% HS for 6 days with medium changes every other day.
1-4. 골격근 세포 독성 및 세포 증식 활성 분석1-4. Analysis of skeletal muscle cytotoxicity and cell proliferation activity
세포독성평가는 96 웰 플레이트에 1 Х 105로 세포를 파종하고 24 시간 후 상기 실시예 1-2에 분리된 [화학식 1]의 화합물을 24 시간 동안 처리하고, MTT 분석을 사용하여 세포 독성 평가를 수행하였다. 포르마잔 결정(formazan crystals)을 DMSO에 용해시키고, 540nm에서 ELISA plate reader(BioTek Instruments, Inc., Winooski, VT, USA)를 사용하여 흡광도를 측정하였다. 화합물이 처리되지 않은 대조군 세포에서 생성된 포르마잔의 광학 밀도는 100 % 생존력을 나타내는 것으로 간주하였다.Cytotoxicity was evaluated by seeding the cells in 1 Х 10 5 in a 96-well plate, treating the compound of [Formula 1] isolated in Example 1-2 for 24 hours after 24 hours, and evaluating cytotoxicity using the MTT assay. was performed. Formazan crystals were dissolved in DMSO, and absorbance was measured at 540 nm using an ELISA plate reader (BioTek Instruments, Inc., Winooski, VT, USA). The optical density of formazan produced in control cells untreated with the compound was considered to represent 100% viability.
골격근 세포 증식활성을 평가하기 위해 BrdU 분석(Millipore, Billerica, MA, USA)을 사용하였다. 96 웰 플레이트에 5 Х 104로 세포를 파종하고 파종 48 시간 후, 성장 배지 (10% FBS를 포함하는 DMEM)를 분화 배지 (2% HS를 포함하는 DMEM)로 교체하고 분화 기간 동안 격일로 실시예 1-2에서 분리된 화합물을 처리하였다. 마지막으로 분화 유도 6 일 후 BrdU assay를 이용하여 세포 증식 활성을 측정 하였다.BrdU assay (Millipore, Billerica, MA, USA) was used to evaluate the skeletal muscle cell proliferation activity. Cells were seeded in 96-well plates with 5 Х 10 4 and 48 hours after seeding, the growth medium (DMEM containing 10% FBS) was replaced with differentiation medium (DMEM containing 2% HS) and performed every other day during the differentiation period. The compound isolated in Example 1-2 was treated. Finally, 6 days after differentiation induction, cell proliferation activity was measured using the BrdU assay.
1-5. Western blot 분석1-5. Western blot analysis
본 발명에 따른 화합물의 근 신생 신호 전달 캐스케이드에 관련된 단백질의 발현 분석을 확인하기 위해 Western blot 분석을 수행하였다. 본 발명에 따른 화합물은 세포분화기간 동안 분화 배지 (2% HS를 함유하는 DMEM)로 처리되었다. 이후 세포질 및 핵 단백질을 수집하고 세포 단백질을 12% 소듐 도데실 설페이트 (SDS)-폴리 아크릴 아미드 겔 전기 영동 (PAGE)으로 분리하여 니트로 셀룰로오스 막으로 옮겼다. 막을 5% 탈지유 (0.2% Tween-20을 함유하는 Tris 완충 식염수에서)로 차단하고 관련 1 차 항체(1 : 5% 탈지유에 1000 희석)와 함께 4 ℃에서 밤새 배양하고, 골격근 세포 합성을 억제하거나 활성화하는 단백질을 분석하였다. 다음으로, HRP- 접합된 2차 항체 (5% 탈지유에서 1 : 3000 희석)를 막에 첨가하고 실온에서 90분 동안 배양하였다. 밴드는 화학 발광 기판을 사용하여 개발되었고 eVo-6 카메라가 장착된 FUSION FX Spectra 프로그램(Vilber Lourmat, Marne-La-Vallιe, France)을 사용하여 촬영하였다. 밴드 강도는 Image J 프로그램을 사용하여 정량화되었다. Western blot analysis was performed to confirm the expression analysis of proteins related to the myogenesis signal transduction cascade of the compound according to the present invention. The compounds according to the present invention were treated with a differentiation medium (DMEM containing 2% HS) during the cell differentiation period. Cytoplasmic and nuclear proteins were then collected and cellular proteins were separated by 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and transferred to a nitrocellulose membrane. Membranes were blocked with 5% skim milk (in Tris-buffered saline containing 0.2% Tween-20) and incubated overnight at 4 °C with relevant primary antibodies (1:1000 dilution in 5% skim milk) to inhibit skeletal muscle cell synthesis or Activating proteins were analyzed. Next, HRP-conjugated secondary antibody (diluted 1:3000 in 5% skim milk) was added to the membrane and incubated for 90 minutes at room temperature. Bands were developed using a chemiluminescent substrate and photographed using the FUSION FX Spectra program (Vilber Lourmat, Marne-La-Vallιe, France) equipped with an eVo-6 camera. Band intensities were quantified using the Image J program.
실시예 2. 본 발명에 따른 화합물의 골격근 세포 분화 활성 확인Example 2. Confirmation of skeletal muscle cell differentiation activity of the compound according to the present invention
상기 실시예 1에서 분리한 [화학식 1]로 표기되는 화합물에 대한 C2C12 myoblasts의 cell viability를 3-(4-5-dimethyl-2yl)-2-5-diphynyltetrasolium bromide (MTT) 분석으로 측정한 결과, 도 2a에 나타낸 바와 같이 [화학식 1]로 표기되는 화합물은 50 μM의 농도에서 C2C12 세포에 대한 세포 독성 효과를 나타내지 않았다. As a result of measuring the cell viability of C2C12 myoblasts for the compound represented by [Formula 1] isolated in Example 1 by 3-(4-5-dimethyl-2yl)-2-5-diphynyltetrasolium bromide (MTT) analysis, As shown in Figure 2a, the compound represented by [Formula 1] did not show a cytotoxic effect on C2C12 cells at a concentration of 50 μM.
이에 더하여, 5-bromo-2'-deoxyuridine (BrdU) 세포 증식 분석방법을 사용하여 [화학식 1]로 표기되는 화합물의 골격근 세포 분화 활성을 평가하였다. 그 결과, 도 2b에 나타난 바와 같이, 본 발명에 따른 화합물은 대조군(control)에 비해 myoblast의 분화를 유의하게 증가시키는 것을 확인하였다. 상기 결과로부터 부추에서 새롭게 분리 한 화합물은 골격근 성장 조절 효과를 나타낸다는 것을 알 수 있었다.In addition, the skeletal muscle cell differentiation activity of the compound represented by
실시예 3. 본 발명의 화합물 처리에 따른 골격근 성장 관련 신호 전달 경로 조절 확인Example 3. Confirmation of regulation of skeletal muscle growth-related signal transduction pathway by treatment with the compound of the present invention
3-1. PI3K/Akt/mTOR 신호 전달 경로 상향 조절3-1. Upregulation of the PI3K/Akt/mTOR signaling pathway
실시예 1-5에 개시된 바와 같이 Western blot을 통해 골격근 성장 관련 신호 전달 경로를 확인한 결과, 도 3a 내지 3g에 나타낸 바와 같이 본 발명의 화합물은 대조군(control)에 비해 p-PI3K, p-Akt, p-FoxO1, p-mTOR, p-70S6K 및 MyoD 단백질 발현 수준을 유의하게 증가시켰다. 즉, 본 발명에 따른 화합물은 p-PI3K/Akt를 통한 p-mTOR/p70S6K를 통해 근육 세포 성장을 유도하였다고 유추할 수 있다.As disclosed in Examples 1-5, as a result of confirming the skeletal muscle growth-related signal transduction pathway through Western blot, as shown in Figs. 3a to 3g, the compounds of the present invention were p-PI3K, p-Akt, The protein expression levels of p-FoxO1, p-mTOR, p-70S6K and MyoD were significantly increased. That is, it can be inferred that the compound according to the present invention induced muscle cell growth through p-PI3K/Akt and p-mTOR/p70S6K.
상기 결과들로부터, 본 발명에 따른 화합물이 PI3K/Akt/mTOR 신호 전달 경로를 활성화하는 것을 알 수 있으며, 이에 따라, 골격근 발달에 관여하는 핵의 인자인 MyoD의 발현에 더 많은 영향을 미친 것으로 추론 할 수 있다. 따라서, 부추에서 분리된 [화학식 1]의 화합물이 PI3K/Akt/mTOR 경로를 촉진함으로써 골격근 성장 및 발달 효과를 나타낸다는 것을 알 수 있었다.From the above results, it can be seen that the compound according to the present invention activates the PI3K/Akt/mTOR signaling pathway, and accordingly, it is inferred that it has a greater effect on the expression of MyoD, a nuclear factor involved in skeletal muscle development. can do. Therefore, it was found that the compound of [Formula 1] isolated from leek exhibits skeletal muscle growth and development effects by promoting the PI3K/Akt/mTOR pathway.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.The above description of the present invention is for illustrative purposes, and those skilled in the art can understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, the embodiments described above should be understood as illustrative in all respects and not limiting.
Claims (10)
[화학식 1]
A pharmaceutical composition for preventing or treating sarcopenia, comprising a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
[Formula 1]
상기 조성물은 근손실 억제 활성을 갖는 것을 특징으로 하는, 약학적 조성물.According to claim 1,
The composition is characterized in that it has a muscle loss inhibitory activity, a pharmaceutical composition.
상기 조성물은 근육세포의 성장 및 분화를 유도시키는 것을 특징으로 하는, 약학적 조성물.According to claim 1,
The pharmaceutical composition, characterized in that the composition induces the growth and differentiation of muscle cells.
상기 조성물은 PI3K/Akt/mTOR 신호 전달 경로의 활성화를 통해 근육세포의 성장 및 분화를 유도시키는 것을 특징으로 하는, 약학적 조성물.According to claim 1,
The pharmaceutical composition, characterized in that the composition induces the growth and differentiation of muscle cells through the activation of the PI3K / Akt / mTOR signal transduction pathway.
상기 화합물은 부추로부터 추출 및 분리된 것을 특징으로 하는, 약학적 조성물.According to claim 1,
Characterized in that the compound is extracted and isolated from leek, a pharmaceutical composition.
[화학식 1]
A health functional food composition for preventing or improving sarcopenia, comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof.
[Formula 1]
상기 조성물은 근손실 억제 활성을 갖는 것을 특징으로 하는, 건강기능식품 조성물.According to claim 6,
The composition is characterized in that it has a muscle loss inhibitory activity, health functional food composition.
상기 조성물은 근육세포의 성장 및 분화를 유도시키는 것을 특징으로 하는, 건강기능식품 조성물.According to claim 6,
The composition is characterized in that for inducing the growth and differentiation of muscle cells, health functional food composition.
상기 조성물은 PI3K/Akt/mTOR 신호 전달 경로의 활성화를 통해 근육세포의 성장 및 분화를 유도시키는 것을 특징으로 하는, 건강기능식품 조성물.According to claim 6,
The composition is a functional health food composition, characterized in that it induces the growth and differentiation of muscle cells through the activation of the PI3K / Akt / mTOR signal transduction pathway.
상기 화합물은 부추로부터 추출 및 분리된 것을 특징으로 하는, 건강기능식품 조성물.According to claim 6,
The compound is characterized in that extracted and separated from leek, health functional food composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210076030A KR102680544B1 (en) | 2021-06-11 | A composition for preventing or treating of sarcopenia containing compounds isolated from allium tuberosum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210076030A KR102680544B1 (en) | 2021-06-11 | A composition for preventing or treating of sarcopenia containing compounds isolated from allium tuberosum |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220167014A true KR20220167014A (en) | 2022-12-20 |
KR102680544B1 KR102680544B1 (en) | 2024-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH02233610A (en) | Vascularization inhibitor | |
DE19523502A1 (en) | Kappa opiate agonists for inflammatory bowel diseases | |
WO2018207790A1 (en) | AGENT FOR PROMOTING DECOMPOSITION AND EXCRETION OF AMYLOID-β | |
US11135178B2 (en) | Thymol and carvacol for use in medicine | |
EP3559892A1 (en) | Methods for treating mitochondrial disorders | |
KR102680544B1 (en) | A composition for preventing or treating of sarcopenia containing compounds isolated from allium tuberosum | |
KR20220167014A (en) | A composition for preventing or treating of sarcopenia containing compounds isolated from allium tuberosum | |
DE112013006260T5 (en) | Alpinia SPP. Extracts for the treatment of irritable bowel syndrome | |
KR20220167012A (en) | A composition for preventing or treating of sarcopenia containing novel compounds isolated from allium tuberosum | |
KR20160035641A (en) | phloretine sulfonate and compositions for improving skin conditions comprising phloretine sulfonate | |
KR20230139239A (en) | A composition for preventing or treating of sarcopenia containing compounds isolated from Morus alba Linne | |
KR20200063772A (en) | Composition for anti-inflammation comprising extract of mealworm containing ginsenoside Re | |
KR20230139238A (en) | A composition for preventing or treating of sarcopenia containing compounds isolated from Morus alba Linne | |
EP0550703B1 (en) | Plant-based medicament for enhancing and controlling the tone of smooth-muscle organs | |
KR20100016096A (en) | Novel use of genistein | |
AU2019261476B2 (en) | Composition for preventing and treating muscular disease | |
Boyd | The Acute Oral Toxicity of the Herbicide Chlorpropham in Albino Rats: Effect of Diets Containing Varying Amounts of Protein | |
WO2009093353A1 (en) | Medicinal composition | |
CA3127291A1 (en) | Method for enhancing .beta.-adrenergic response | |
KR20230142287A (en) | A composition for preventing or treating of non-alcoholic steatohepatis(NASH) containing compounds isolated from Albizzia julibrissin | |
KR20230142291A (en) | A composition for preventing or treating of non-alcoholic steatohepatis(NASH) containing compounds isolated from Albizzia julibrissin | |
WO2018207791A1 (en) | Arc expression promoter | |
US20120201876A1 (en) | Method of managing hypercortisolemia, headache disorders, neuropathic pain and related disorders | |
KR102305178B1 (en) | Composition containing Oxalis obtraiangulata.Maxim extracts for preventing or treating pancreatic cancer | |
KR20130046094A (en) | Medical composition comprising abutilon avicennae extract for preventing or treating inflammatory disease |